论文部分内容阅读
目的探讨厄贝沙坦对2型糖尿病肾病(DN)患者氧化损伤的影响。方法选取24例近期未服用抗氧化药物,且有明显蛋白尿的2型DN患者。厄贝沙坦150mg/d治疗10周,之后300mg/d治疗10周。检测厄贝沙坦治疗前后24h尿蛋白、尿肌酐、尿8-羟基脱氧鸟嘌呤(8-OHdG)、尿超氧化物歧化酶(SOD)和血生化水平。10例健康志愿者的尿液标本作为正常对照。结果与正常对照组比较,DN患者尿8-OHdG水平明显升高(P<0.05),尿SOD明显降低(P<0.01)。经厄贝沙坦150mg/d、300mg/d各治疗10周后,8-OHdG水平均明显降低(P均<0.05),尿SOD均升高(P<0.05)。结论 DN患者氧化损伤明显,厄贝沙坦具有减轻DN患者氧化损伤作用,且无明显副作用。
Objective To investigate the effects of irbesartan on oxidative damage in patients with type 2 diabetic nephropathy (DN). Methods Twenty-four patients with type 2 DN who did not take anti-oxidant drugs and had obvious proteinuria were selected. Irbesartan 150 mg / d for 10 weeks followed by 300 mg / d for 10 weeks. Urine proteinuria, urinary creatinine, 8-OHdG, SOD and blood biochemistry were measured before and after irbesartan treatment. Urine specimens from 10 healthy volunteers served as normal controls. Results Compared with the normal control group, the urinary 8-OHdG level in DN patients was significantly increased (P <0.05) and the urine SOD was significantly decreased (P <0.01). The levels of 8-OHdG were significantly decreased after irbesartan 150 mg / d, 300 mg / d for 10 weeks (all P <0.05), while the urine SOD increased (P <0.05). Conclusion The oxidative damage of DN patients is obvious. Irbesartan can reduce the oxidative damage of DN patients and has no obvious side effects.